Date: 2018-03-13
Type of information: Development agreement
Compound: small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG)
Company: Ideaya Biosciences (USA - CA) Cancer Research UK (UK)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
- enzyme inhibitor/PARG inhibitor. PARG is a cellular enzyme that breaks down Poly(ADP-ribose), a post-translational modification that modulates protein function required for DNA repair. Inhibition of PARG in cancer cells with highly-active PARP results in depletion of cellular NAD. NAD is an essential cofactor in cellular respiration, and its depletion results in a dramatic decrease in cellular ATP and cancer cell death.
Disease:
Details:
Financial terms:
Latest news:
Is general: Yes